Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan

Journal of Research in Medical Sciences

Volumn 13, Issue 6, 2008, Pages 317-323

  Dastjerdi, Mehdi Nikbahkt ^a   Salehi, Mansoor ^a   Mohajeri, Mohammad Reza ^b   Morsali, Fereshteh ^c   Sadeghi, Hamid Mirmohammad ^a   Esfandiary, Ebrahim ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Lab of Pathology   (Iran)

^c Clinic of Dentistry   (Iran)

Author keywords

Arginine; Colorectal adenocarcinoma; Polymorphism; Proline; TP53

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; ENDEMIC DISEASE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 63249132897     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW et al. p53-dependent inhibition of cyclindependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76(6):1013-1023.
2. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001; 264(1):56-66.
3. Sherr CJ. Principles of tumor suppression. Cell 2004; 116(2):235-246.
4. Kaelin WG, Jr. The p53 gene family. Oncogene 1999; 18(53):7701-7705.
5. Robles AI, Harris CC. p53-mediated apoptosis and genomic instability diseases. Acta Oncol 2001; 40(6):696-701.
6. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187(1):112-126.
7. Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD. p53 Mutations in human cholangiocarcinoma: a review. Liver Int 2005; 25(4):704-716.
8. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003; 21(3):292-300.
9. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19(6):607-614.
10. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1(3):233-240.
11. Sreeja L, Syamala V, Raveendran PB, Santhi S, Madhavan J, Ankathil R. p Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest 2008; 26(1):41-46.
12. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996; 93(26):15335-15340.
13. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19(2):1092-1100.
14. Dumont P, Leu JI, Della PA, III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33(3):357-365.
15. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393(6682):229-234.
16. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94(2):153-156.
17. Rupnarain C, Dlamini Z, Naicker S, Bhoola K. Colon cancer: genomics and apoptotic events. Biol Chem 2004; 385(6):449-464.
18. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002; 137(7):603-612.
19. Cannon-Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW. Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 1988; 319(9):533-537.
20. Houlston RS, Collins A, Slack J, Morton NE. Dominant genes for colorectal cancer are not rare. Ann Hum Genet 1992; 56(Pt 2):99-103.
21. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96(10):2992-3003.
22. Gazelle GS, McMahon PM, Scholz FJ. Screening for colorectal cancer. Radiology 2000; 215(2):327-335.
23. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9(10):1037-1042.
24. Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP et al. Genetic polymorphisms of p53 and GSTP1,but not NAT2,are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000; 89(5):458-464.
25. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999; 354(9174):218-219.
26. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002.
27. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 2004; 210(2):197-203.
28. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005; 222(1):57-65.
29. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11(12):1684-1688.
30. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004; 25(11):1568-1573.
31. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002; 183(2):123-130.
32. Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003; 82(2):111-120.
33. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 2002; 112(1):116-119.
34. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999; 29(3):697-702.
35. Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12(9):1426-1.
36. Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004; 130(12):728-732.
37. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 23(10):1954-1956.
38. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF et al. Association of the TP53 codon 7 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007; 37(5):385-390.
39. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis.
40. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996; 17(2):261-264.
41. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002; 181(1):81-85.
42. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001; 109(1-2):25-34.
43. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F et al. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004; 6(5):529-535.
44. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991; 86(4):369-370.
45. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995; 16(7):1461-1464.
46. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006;
47. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44(5):266-270.
48. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25(1):47-54.
49. Kaelin WG, Jr. The emerging p53 gene family. J Natl Cancer Inst 1999; 91(7):594-598.
50. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 2003; 22(34):5252-5260.
51. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003; 36(2):279-283.
52. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11(2):289-292.
53. Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X et al. p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. World J Gastroenterol 2004; 10(19):2775-2778.
54. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25(1):47-54.